RBC Capital raised the firm’s price target on HCA Healthcare to $378 from $329 and keeps an Outperform rating on the shares. The company delivered an “impressive” Q2 beat and raise despite the high expectations, driven by continued demand momentum, favorable Medicaid DPP development, and cost control, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare’s Q2 results highlight strong utilization, says Goldman Sachs
- Early notable gainers among liquid option names on July 23rd
- HCA Healthcare Announces Strong Q2 Performance and Dividend
- HCA Healthcare raises FY24 EPS view to $21.60-$22.80 from $19.70-$21.20
- HCA Healthcare reports Q2 EPS $5.53, consensus $4.88